Genesis Drug Discovery and Development Expands Its Presence in the Clinical Space by Acquiring STATKING Clinical Services
News provided by
Share this article
® (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD
3) announced today that it has acquired the Cincinnati-based CRO STATKING Clinical Services. Established in 1989, STATKING provides clinical trial services, including clinical trial management, protocol development, biostatistics, clinical data management, clinical study monitoring, medical writing, medical monitoring, safety reporting, and project management for the regulatory approval of novel drug and medical device products.
STATKING Clinical Services
"We are very pleased to have STATKING join GBG, and this acquisition demonstrates our commitment to making GD